New Market Development

United Arab Emirates

The 57 member states of the Organization of Islamic Cooperation (OIC), where the majority of the nearly 2 billion muslims (approx. 25% of the world’s population) live today, are experiencing an increasing demand for halal pharmaceuticals.

There are several therapeutic areas of interest to muslim populations today, including halal-certified treatments for cardiovascular diseases, insulin to treat diabetes, biological drugs for cancer treatments, halal vaccines, nutraceuticals and dietary supplements for maintaining good health and preventing chronic diseases.

Major pharmaceutical companies are already leveraging halal compliance for their currently marketed drugs as a way to compete in certain muslim markets where high generic or biosimilar competition exists for similar drugs.

Halal Pharmacore

Is up-to-date on all important viable halal pharmaceutical markets of interest
Has a clear understanding of the cultural, economic, regulatory, and political factors that impact business practices in the halal pharma markets of interest.
Has identified the highest market potential halal pharmaceutical drug candidates
Develops and Validates halal compliant manufacturing processes using our highly skilled scientific and engineering teams armed with a wide spectrum of capabilities in both chemical and biological drug development.
Accesses pharmaceutical-grade supply chains supported by comprehensive logistics infrastructures
Manufactures halal pharmaceutical drugs in state-of-the-art halal compliant EU GMP facilities
Certifies drugs as Halal with regulatory agencies in various markets of interest
Works with Distribution Partners with a strong reputation on a national scale executed through multiple branches and a deep understanding of the new local markets we choose to target

You are looking to expand into the Halal Pharmaceutical Market using your exist drug portfolio, we welcome the opportunity to help you achieve this goal in support of our mission.